Elliot Wilbur
Stock Analyst at Raymond James
(1.52)
# 3,276
Out of 4,761 analysts
54
Total ratings
31.11%
Success rate
-3.55%
Average return
Main Sectors:
Stocks Rated by Elliot Wilbur
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
ADMA ADMA Biologics | Maintains: Strong Buy | $18 → $25 | $15.84 | +57.83% | 7 | Nov 8, 2024 | |
ANIP ANI Pharmaceuticals | Maintains: Outperform | $81 → $83 | $57.94 | +43.25% | 12 | Sep 18, 2024 | |
SLGL Sol-Gel Technologies | Downgrades: Outperform | $6 → $4 | $0.58 | +589.66% | 8 | Aug 19, 2024 | |
OGN Organon & Co. | Initiates: Outperform | $33 | $15.49 | +113.04% | 1 | Mar 16, 2023 | |
PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $25.34 | +69.69% | 6 | Mar 6, 2023 | |
PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $2.99 | +3,913.38% | 3 | Sep 6, 2022 | |
VTRS Viatris | Downgrades: Market Perform | n/a | $11.25 | - | 3 | Mar 1, 2022 | |
TEVA Teva Pharmaceutical Industries | Downgrades: Market Perform | n/a | $16.74 | - | 4 | Oct 28, 2021 | |
ZTS Zoetis | Downgrades: Market Perform | n/a | $160.46 | - | 4 | Jul 16, 2021 | |
ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $11.02 | - | 1 | Jan 10, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $5.19 | - | 2 | Jan 17, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $31.28 | - | 3 | Nov 9, 2017 |
ADMA Biologics
Nov 8, 2024
Maintains: Strong Buy
Price Target: $18 → $25
Current: $15.84
Upside: +57.83%
ANI Pharmaceuticals
Sep 18, 2024
Maintains: Outperform
Price Target: $81 → $83
Current: $57.94
Upside: +43.25%
Sol-Gel Technologies
Aug 19, 2024
Downgrades: Outperform
Price Target: $6 → $4
Current: $0.58
Upside: +589.66%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $15.49
Upside: +113.04%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $25.34
Upside: +69.69%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $2.99
Upside: +3,913.38%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $11.25
Upside: -
Teva Pharmaceutical Industries
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $16.74
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $160.46
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $11.02
Upside: -
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $5.19
Upside: -
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $31.28
Upside: -